Leerink Partnrs Issues Positive Forecast for LENZ Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at Leerink Partnrs boosted their Q3 2025 earnings per share estimates for LENZ Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of ($0.80) for the quarter, up from their prior forecast of ($0.87). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($0.45) EPS.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.02.

A number of other equities research analysts have also weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday, May 8th. TD Cowen initiated coverage on LENZ Therapeutics in a research note on Tuesday, March 18th. They set a "buy" rating and a $60.00 price target on the stock. Citigroup lifted their price objective on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Finally, Piper Sandler initiated coverage on LENZ Therapeutics in a research report on Monday, April 14th. They set an "overweight" rating and a $51.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, LENZ Therapeutics presently has an average rating of "Buy" and an average price target of $46.60.

LENZ Therapeutics Stock Performance

LENZ traded up $0.05 during trading on Monday, reaching $27.39. The company's stock had a trading volume of 33,050 shares, compared to its average volume of 186,143. LENZ Therapeutics has a 52-week low of $14.42 and a 52-week high of $38.93. The company's fifty day moving average price is $24.99 and its 200-day moving average price is $27.33. The company has a market capitalization of $770.78 million, a price-to-earnings ratio of -15.42 and a beta of 0.41.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in LENZ Therapeutics in the 4th quarter valued at $29,000. KLP Kapitalforvaltning AS purchased a new position in LENZ Therapeutics in the 4th quarter valued at about $46,000. Tower Research Capital LLC TRC boosted its position in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after buying an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in shares of LENZ Therapeutics during the fourth quarter worth about $67,000. Finally, Banque Transatlantique SA bought a new position in shares of LENZ Therapeutics during the first quarter worth about $119,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.